ZNF417

Across TCGA pan-cancer cohorts, ZNF417 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ZNF417 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ZNF417 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZNF417 expression acts as an unfavorable survival marker, although some lineages such as GBM and HNSC show a favorable association.

PDAC, GBM, and HNSC are the cancer types where ZNF417 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.191	0.616	.003	17	view →
GBM	OS	Median	All	0.704	0.231	.031	2	view →
HNSC	DFS	Tertile	IV	0.886	0.600	.043	1	view →
CCRCC	DFS	Tertile	All	0.915	0.645	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ZNF417–PDAC (DFS)

Open the PDAC breakdown →